trending Market Intelligence /marketintelligence/en/news-insights/trending/0hoc5a1zno8i-ube_zrxsa2 content esgSubNav
In This List

Aevi Genomic director to retire

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Aevi Genomic director to retire

Wilbur Gantz will not stand for re-election to the board of Aevi Genomic Medicine Inc. at the 2018 annual stockholders meeting.

Gantz, who informed the company March 19 that he plans to retire, will continue to serve until his current term expires at the annual meeting.

Gantz has been a director of the Pennsylvania-based clinical stage biopharmaceutical company since October 2013.